原发性胆汁性肝硬化患者肝组织转化生长因子β-1表达水平变化

doi:10.3969/j.issn.1672-5069.2018.02.020

Abstract

Abstract: Objective To investigate the expression of transforming growth factor β-1（TGFβ-1） in liver tissues of patients with primary biliary cirrhosis（PBC） and its relationship with liver fibrosis. Methods 52 patients with PBC and 20 healthy persons were recruited in our hospital. The patients with PBC received liver biopsies and 20 normal liver tissues from the Department of Pathology in our hospital served as control. The expression of TGFβ-1 in liver tissues was detected immunohistochemistry and serum tumor necrosis factor α（TNF-α） and interleukin 6（IL-6） levels were detected by ELISA. Results TGFβ-1 was not expressed or little expressed in normal liver tissues,while it was highly expressed in cytoplasm of hepatic parenchyma cells in patients with PBC;serum TNF-α and IL-6 levels in patients with PBC were （28.71±13.54） pg/ml and （21.3±9.4） pg/ml,significantly higher than those in control group[（21.3±15.4） pg/ml and （2.1±1.6） pg/ml,respectively,P<0.01];The expression level of TGFβ-1 in liver tissues and serum levels of TNF-α and IL-6 in 7 patients with PBC with liver fibrosis stage S0 were（0.5±0.2） 10-2,（7.1±4.1） pg/ml and（5.1±1.0） pg/ml,significantly lower than those in 12 with stage S1 [（4.2±1.3） 10-2,（18.6±6.2） pg/ml and （11.5±3.6） pg/ml,P<0.01],or in 18 with stage S2 [（6.9±1.2） 10-2,（27.3±9.9） pg/ml and （19.4±4.1） pg/ml,P<0.01],or in 9 with stage S3[（13.3±15.1） 10-2,（39.7±15.18） pg/ml and（27.3±8.1） pg/ml,P<0.01] or in 6 with stage S4 [（21.2±17.1） 10-2,（53.4±17.3） pg/ml,（47.8±11） pg/ ml, respectively,P<0.01];the expression level of TGFβ-1 in liver tissues and serum levels of TNF-α and IL-6 in 15 patients with Child-Pugh class A were（1.9±1.6） 10-2,（12.2±3.1） pg/ml and（7.3±2.5） pg/ml,significantly lower than [（15.9±13.6） 10-2,（32.9±8.6） pg/ml an（21.8±6.3） pg/ml,P<0.01）] in 25 patients with Child-Pugh class B or [（22.6±18.5） 10-2,（49.1±19.3） pg/ml and（45.5±12.7） pg/ml,P<0.01] in 12 patients with Child-Pugh class C. Conclusion The expression of TGFβ-1 in liver tissues and serum TNF-α and IL-6 levels increase in patients with PBC,which might be related to the formation of liver fibrosis and the deteriorated liver function.

Key words: Primary biliary cirrhosis, Liver fibrosis, Transforming growth factor β-1;, Tumor necrosis factor α, Interleukin 6

Qin Wei, Chen Yuping, Yang Zhao, et al. Expression of transforming growth factor β-1 in liver tissues of patients with primary biliary cirrhosis and its relationship with liver fibrosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 237-240.

References

[1] Floreani A,Franceschet I,Cazzagon N,et al.Extrahepatic autoimmune conditions are associated with primary biliary cirrhosis. Clin Rev Aller Immunol,2015,48(3):192-197.
[2] 李萍英,陆伦根. 原发性胆汁性肝硬化药物治疗进展. 实用肝脏病杂志,2015,18(4):441-444.
[3] Park JH,Yoon J.Schizandrin inhibits fibrosis and epithelial-mesenchymal transition in transforming growth factor-β1-stimulated AML12 cells.Int Immunopharmacol,2015,25(2):276-284.
[4] Falasca K,Reale M,Ucciferri C,et al.Cytokines,hepatic fibrosis and antiretroviral therapy role in neurocognitive disorders HIV-related.Aids Res Human Retrovir,2016,33(3):246-253.
[5] 中华医学会肝病学分会、消化病学分会、感染病学分会. 胆汁淤积性肝病诊断和治疗共识(2015). 实用肝脏病杂志,2016,19(6):Ⅰ-ⅩⅠ.
[6] Chen YX,Huang YH,Zheng WD,et al.Interleukin-10 gene modification attenuates hepatocyte activation of rat hepatic stellate cells in vitro. Mol Med Rep,2013,7(2):371-378.
[7] 黄文琪,许金超,闵峰,等. 吲哚菁绿清除试验对肝硬化患者肝脏储备功能的评估价值. 实用肝脏病杂志,2015,18(5):468-471.
[8] Park SA,Kim MJ,Park SY,et al.EW-7197 inhibits hepatic,renal,and pulmonary fibrosis by blocking TGF-β/Smad and ROS signaling.Cell Mol Lif Sci,2015,72(10):2023-2023.
[9] Park HJ,Kim HG,Wang JH,et al.Comparison of TGF-β,PDGF,and CTGF in hepatic fibrosis models using DMN,CCl4,and TAA. Drug Chem Toxicol,2016,39(1):111-118.
[10] 曾波,李彦.慢性乙型肝炎和肝硬化患者血清骨桥蛋白和TGF-β1水平变化. 实用肝脏病杂志,2017,20(2):240-241.
[11] Wermuth PJ,Li Z,Mendoza FA,et al.Stimulation of transforming growth factor-β1-induced endothelial-to-mesenchymal transition and tissue fibrosis by endothelin-1(ET-1):a novel profibrotic effect of ET-1. Plos One,2016,11(9):e0161988-e0161988.
[12] Liu B,Zhang X,Zhang FC,et al.Aberrant TGF-β1 signaling contributes to the development of primary biliary cirrhosis in murine model.World J Gastroenterol,2013,9(35):5828-5836.
[13] Sant'Anna LB, Hage R,Cardoso MA,et al. Anti-fibrotic effects of human amniotic membrane transplantation in established biliary fibrosis induced in rats. Cell Transplant,2016,25(12):2245-2257.
[14] Meng F,Wang K,Aoyama T,et al.Interleukin-17 signaling in inflammatory,Kupffer cells,and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology,2012,143(3):765-776.
[15] 贾玉杰,赵芳,张彩华,等. 中药肝复康对TNF-α介导的炎症性肝损伤和大鼠肝纤维化的抑制作用.中国微生态学杂志,2016,28(2):146-150.
[16] 薛如意,张丹瑛,吴昊,等. Toll样受体3基因缺陷促进四氯化碳诱导的小鼠肝纤维化损伤. 中国临床医学,2016,23(1):1-5.
[17] Salter ML,Lau B,Mehta SH,et al.Correlates of elevated interleukin-6 and C-reactive protein in persons with or at high risk for HCV and HIV infections. J Acquir Immune Defic Syndr,2013,64(5):488-95.
[18] 李衍飞,邵军,王志鑫,等.泡球蚴囊液对大鼠肝星状细胞TGF-β1、IL-6及TNF-α表达的影响.中国普外基础与临床杂志,2016,23(12):1500-1502.
[19] Oertelt S,Lian ZX,Cheng CM,et al.Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. J Immunol,2006,177(3):1655-60.
[20] Nawaz R,Zahid S,Idrees M,et al.HCV-induced regulatory alterations of IL-1β,IL-6,TNF-α,operative,leading liver en-route to non-alcoholic steatohepatitis. Inflamm Res,2017,66(6):477-486.

Expression of transforming growth factor β-1 in liver tissues of patients with primary biliary cirrhosis and its relationship with liver fibrosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[2]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[3]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[4]	Cheng Hua, Ju Hui, Song Deshun et al. Value of serum angiopoietin-like protein 2 and Golgi protein 73 levels in the diagnosis of hepatic fibrosis in patient with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 494-497.
[5]	Yu Yingfang, Wen Shengbao. Assessment of liver fibrosis with diffusion-weighted magnetic resonance imaging using single, double and stretch index model in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 502-505.
[6]	Zhang Yafei, Ye Jun, Xie Qinxiu, et al. Difference in predicting efficacy of significant liver fibrosis by noninvasive liver fibrosis index in different hospitals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 510-513.
[7]	Zhou Liyun, Li Xiaotian, Li Li. 1,25（OH）₂D₃ inhibits hepatic fibrosis by regulating miR-146a levels in vitro and in vivo [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 333-336.
[8]	Jiang Yi, Liu Bing. Comparison of clinical features and histopathological activity index between patients with chronic hepatitis B and chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 188-191.
[9]	Yusup Tursun, Zhao Yanxia.. Establishment of low-dose diethylnitrosamine-induced liver fibrosis model in rats [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 33-36.
[10]	Guo Xiaoxia, Guo Beiting, Kong Xianglu.. Effects of splenectomy on hepatic fibrosis in mice with poly I:C-induced primary biliary cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 837-841.
[11]	Huang Chunming, Yang Zhan, Nie Yuqiang, et al.. Prediction of liver fibrosis by gamma-glutamyl-transpeptidase-to-platelet ratio in patients with chronic hepatitis B viral infection with normal serum transaminase levels [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 859-862.
[12]	Liu Yingchuan, Zhao Pengcheng, You Ting, et al.. Changes of peripheral blood 25-（OH） 2-D3 levels and peripheral T lymphocyte subsets in patients with primary biliary cirrhosis receiving vitamin D supplementation and ursodeoxycholic acid treatment [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 907-910.
[13]	Zheng Zhenchuan, Xu Xihai.. Pathological and clinical features and factors affecting significant liver fibrosis in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 713-716.
[14]	Liu Jinguo, Wang Baokui. Efficacy of Fufangbiejia Ruanganpian and ursodeoxycholic acid combination in the treatment of patients with primary biliary cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 340-343.
[15]	Ren Tao, Pan Wen, Xu Li, et al. Clinical features of liver cirrhosis in Tibetan minority [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 352-355.